HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CP-471,358

matrix metalloproteinase inhibitor

Also Known As:

3-((4-(4-fluorophenoxy)benzenesulfonyl)-(1-hydroxycarbamoylcyclopentyl)amino )propionic acid

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - CP-471,358: 1
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - CP-471,358: 1

Experts

1.	Bartkowski, Michele: 1 article (02/2005)
2.	Ferrante, Karen: 1 article (02/2005)
3.	Noe, Dennis: 1 article (02/2005)
4.	Planting, André: 1 article (02/2005)
5.	Schöffski, Patrick: 1 article (02/2005)
6.	Verheij, Coleta: 1 article (02/2005)
7.	Verweij, Jaap: 1 article (02/2005)
8.	van der Gaast, Ate: 1 article (02/2005)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2005 - "An open-label phase I study was performed in patients with advanced solid tumors to assess the safety, tolerability, maximal tolerated dose (MTD) and pharmacokinetics of CP-471,358. " 02/01/2005 - "A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors."
2.	Myalgia 02/01/2005 - "The DLT of CP-471,358 was myalgia and arthralgia, an adverse event observed during treatment with most matrix metalloproteinase inhibitors. "
3.	Arthralgia (Joint Pain) 02/01/2005 - "The DLT of CP-471,358 was myalgia and arthralgia, an adverse event observed during treatment with most matrix metalloproteinase inhibitors. "

Related Drugs and Biologics

1.	Matrix Metalloproteinase Inhibitors